ArticleMolecular biology reports2025
LncRNA MEG3 independently collaborates with lncRNA TUG1 to prevent cholesterol efflux in ox-LDL-induced human umbilical vein endothelial cells.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ORMDL3 as Key Regulator of Endothelial Dysfunction in Atherosclerosis via Sphingolipid Biosynthesis.Inflammation · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMaternally expressed gene 3 (MEG3) is an abnormal methylation gene and low expression of lncRNA MEG3 have been observed in coronary heart disease (CHD). This study aims to investigate whether DNA methylation mediates the abnormal expression of lncRNA MEG3 and to explore the underlying mechanism by which lncRNA MEG3 regulates cholesterol efflux.
methodsReal-time quantitative polymerase chain reaction (RT-qPCR) and western blot were used to assess molecular expressions. Oxidized low-density lipoprotein (Ox-LDL) treated human umbilical vein endothelial cells (HUVECs) were established as an in vitro model. Methylation-specific PCR was used to evaluate the methylation level of MEG3. BODIPY-cholesterol assay was performed to examine intracellular cholesterol efflux. Luciferase reporter gene assay was used to verify the interaction between miR-181a-5p and MEG3/ABCA1.
resultsLncRNA MEG3 was downregulated, while taurine upregulated gene 1 (TUG1) was upregulated in patients with CHD. Besides, ox-LDL treatment increased DNMT3B expression, decreased lncRNA MEG3 expression and elevated the level of MEG3 methylation in HUVECs. Further experiments showed that DNMT3B overexpression reduced lncRNA MEG3 expression and enhanced MEG3 methylation. Additionally, silencing MEG3 decreased ABCA1 expression to prevent cholesterol efflux in HUVECs. The interaction between miR-181a-5p and MEG3/ABCA1 were also confirmed. Rescue experiments suggested that MEG3 knockdown downregulated ABCA1 expression via miR-181a-5p, thereby preventing cholesterol efflux in HUVECs. Furthermore, the results showed that MEG3 collaborated with TUG1 in an independent manner to block ABCA1 mediated-cholesterol efflux in HUVECs.
conclusionDownregulation of lncRNA MEG3, mediated by DNMT3B, prevents cholesterol efflux through miR-181a-5p/ABCA1 axis in ox-LDL-induced HUVECs. Moreover, MEG3 collaborated with TUG1 in an independent manner to prevent ABCA1 mediated-cholesterol efflux in HUVECs.
Indexed as
Identifiers
40293536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.